Skip to main content

Table 1 Patient characteristics by initial GC dose group

From: Treatment-related damage in elderly-onset ANCA-associated vasculitis: safety outcome analysis of two nationwide prospective cohort studies

  Low-dose (n = 59) Medium-dose (n = 52) High-dose (n = 68)
Male/female 27/32 18/34 23/45
Age (years), mean ± SD (median) 80.9 ± 3.9 (80) 79.9 ± 3.6 (80) 79.1 ± 3.6 (78)
Disease classification, n
 EGPA 2 2 3
 GPA 5 9 14
 MPA 42 33 38
 Unclassifiable 10 8 13
Disease severity, n (%)
 Localized 1 3 3
 Early systemic 12 14 18
 Systemic 34 27 35
 Severe 12 8 12
BVAS, mean ± SD 15.8 ± 6.3 17.3 ± 6.0 15.4 ± 7.2
MPO-ANCA–positive, n (%) 55 (93) 49 (94) 64 (94)
PR3-ANCA–positive, n (%) 0 2 (4) 3 (4)
Serum creatinine (mg/dL), mean ± SD 3.11 ± 3.56 2.36 ± 2.15 1.59 ± 1.31
Interstitial lung disease, n (%) 29 (49) 24 (46) 29 (43)
Treatment
 Initial daily dose of PSL (mg/kg/day), mean ± SD#, † 0.47 ± 0.10 0.69 ± 0.05 0.98 ± 0.18
 Cyclophosphamide, n (%) 8 (13) 10 (19) 36 (53)
  1. Comparisons among groups were made using the Mann–Whitney U test or Fisher’s exact probability test. Statistical significance was determined by using Bonferroni correction (< 0.05/3). ANCA antineutrophil cytoplasmic antibody, BVAS Birmingham Vasculitis Activity Score, EGPA eosinophilic granulomatosis with polyangiitis, GPA granulomatosis with polyangiitis, MPA microscopic polyangiitis, MPO myeloperoxidase, PR3 proteinase 3, PSL prednisolone, SD standard deviation
  2. #Medium-dose vs. high-dose group
  3. Low-dose vs. high-dose group